文献速递血栓与止血

疫苗诱导免疫性血栓性血小板减少症(VITT):一种临床表现异质的新型临床病理实体

Vaccine-induced immune thrombotic thrombocytopenia (VITT) - a novel clinico-pathological entity with heterogeneous clinical presentations.
PubMed 文献 · Br J Haematol · 2021-06-22

本文报道4例确诊VITT患者,均在接受ChAdOx1 nCoV-19疫苗后出现血小板减少、血栓形成和D-二聚体升高的三联征。按现行指南,每例患者在就诊时均可能被归类为VITT低概率,提示当前指南可能缺乏识别早期VITT的敏感性,需提高临床警觉。

要点

  • VITT三联征为血小板减少、血栓形成和D-二聚体升高,出现在ChAdOx1 nCoV-19疫苗接种后。
  • 4例确诊VITT患者按现行指南就诊时均可能被归为低概率,提示指南敏感性不足。
  • 随着症状早期识别,VITT临床表现更趋异质,需警惕漏诊或延迟诊断。

核心结论

  • 当前指南可能缺乏识别早期VITT的敏感性,存在漏诊或延迟诊断风险。
  • VITT临床表现呈异质性谱系,需提高临床警觉并随病理生理认识更新调整诊断策略。

研究设计与样本

  • 病例系列研究,纳入4例确诊VITT患者。

主要发现

  • 4例确诊VITT患者按所用指南均可能就诊时被归类为VITT低概率。
  • 所有指南可快速识别接种ChAdOx1 nCoV-19后具备血小板减少、血栓形成和D-二聚体升高完整三联征的患者。

关键数值与推荐

  • 现行指南以接种ChAdOx1 nCoV-19后血小板减少、血栓形成和D-二聚体升高三联征快速识别VITT。

临床怎么用

  • 对接种ChAdOx1 nCoV-19后出现相关症状者,不应仅凭指南低概率分类排除VITT。
  • 需结合临床表现异质性提高对早期VITT的警觉,避免漏诊或延迟诊断。

局限性

  • 本文为4例病例系列,样本量小。
  • 未报告具体实验室数值、阈值及指南推荐条款细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a novel entity that emerged in March 2021 following reports of unusual thrombosis after ChAdOx1 nCoV-19, (AstraZeneca) vaccination. Following the recognition of this syndrome, multiple consensus guidelines have been released to risk stratify patients presenting with possible symptoms after ChAdOx1 nCoV-19 vaccination. All guidelines rapidly identify VITT in patients with the complete triad of thrombocytopenia, thrombosis and elevated D-dimers after ChAdOx1 nCoV-19 vaccination. However, with earlier recognition of the associated symptoms, the clinical manifestations are likely to be more heterogeneous and represent an evolving spectrum of disease. In this setting, current guidelines may lack the sensitivity to detect early cases of VITT and risk missed or delayed diagnoses. The broad clinical phenotype and challenges associated with diagnosis of VITT are highlighted in our present case series of four patients with confirmed VITT. Dependent on the guidance used, each patient could have been classified as a low probability of VITT at presentation. The present study highlights the issues associated with the recognition of VITT, the limitations of current guidance and the need for heightened clinical vigilance as our understanding of the pathophysiology of this novel condition evolves.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Lavin M, Elder PT, O'Keeffe D, et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT) - a novel clinico-pathological entity with heterogeneous clinical presentations. Br J Haematol. 2021. PMID: 34159588. doi:10.1111/bjh.17613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。